Modality
Gene Editing
MOA
BiTE
Target
Tau
Pathway
T-cell
DravetOvarian Ca
Development Pipeline
Preclinical
Dec 2025
→ Aug 2031
PreclinicalCurrent
NCT03974204
2,921 pts·Ovarian Ca
2025-12→2031-08·Recruiting
2,921 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-015.3y awayInterim· Ovarian Ca
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2031-08-01 · 5.3y away
Ovarian Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03974204 | Preclinical | Ovarian Ca | Recruiting | 2921 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ | |
| AXS-4984 | Axsome | Preclinical | JAK2 |